The Imaging Core will perform all MR and bioluminescence imaging studies on mouse tumor models for Projects 1 and 2. In addition, the Imaging Core is responsible for all preclinical and clinical data archiving, post-processing and analysis. Core personnel will provide services including: (a) define and implement data acquisition/imaging sequences; (b) assist with animal preparation for imaging; (c) perform all data collection on the 9.4 Tesla MRI, 7 Tesla MRI and Caliper bioluminescence imaging systems; (d) preliminary data processing/image reconstruction and quantitative analysis including PRM analysis for both preclinical (Projects 1 and 2) and clinical imaging data (Project #3) and outcomes data; (e) secure archival of raw data and network transfer of reconstructed data from off-site facilities; (f) scheduling of imaging experiments; and (g) provide support to Program Investigators in technical design and implementation of imaging experiments. These services are designed, in part, after a "clinical MRI service" model since continual, high-volume animal scanning is essential for the success of each project Specific animal MRI protocols will vary with each project, but will primarily include serial studies using: standard T2-weighted; Tl-weighted dynamic contrast enhanced; multislice quantitative water diffusion mapping and dynamic contrast enhancing permeability mapping. The Core will also facilitate the identification of the spatial coordinates needed for biopsy of mouse gliomas using stereotaxic procedures and facilite this activity. The Core will also assist with transfer of MR data to Imbio, LLC for offsite analysis of diffusion and perfusion MRI data sets acquired at multiple sites. Dr. Galban will serve as Core B Director. Dr. Galban has extensive experience in small animal imaging research as well as digital image processing and analysis of clinical MRI data. A Co-investigator and staff will assist Dr. Galban with adapting image processing algorithm's and associated analysis software to ensure the needs of this programmatic research effort are fully met.

Overall, this research effort will provide the imaging data and analysis for evaluating improved approaches including the use of molecularly targeted therapies for the treatment of malignant brain tumors. Additionally, imaging biomarkers for early assessment of treatment response and recurrence will be identified and validated which will lead to individualization of patient care.